No Data
No Data
Zhi Jiang Biological (688317.SH): Cumulative spending of 22.73 million yuan to repurchase 0.74% of shares.
On ****, GeLongHui reported that ZhiJiang Bio(688317.SH) has announced that as of May 31, 2024, the company has repurchased 1,442,987 of its own shares through the Shanghai Stock Exchange trading system by means of centralized competitive bidding method, accounting for 0.74% of the total shares of the company, with a highest price of 17.29 yuan/share, a lowest price of 13.79 yuan/share, and a total amount paid for the shares of 227,321,140.99 yuan (excluding stamp duty, transaction commission and other transaction fees).
Zhijiang Biotech (688317.SH): 3 products obtained relevant certification from the Food and Drug Administration of Thailand
Zhitong Finance App News, Zhijiang Biotech (688317.SH) announced that the company recently obtained relevant certification from the Food and Drug Administration of Thailand. The product names are High-Risk Human Papillomavirus (HPV) and Genotyping 16&18 Diagnostic Kit (PCR-fluorescence) high-risk human papillomavirus (HPV) nucleic acid testing and 16/18 typing kit (fluorescence PCR method), High-risk Hum
Zhijiang Biotech (688317.SH): cumulative repurchase of 0.61% of shares
Gelonghui, May 7, 丨 Zhijiang Biotech (688317.SH) announced that as of April 30, 2024, the company had repurchased a total of 1,184,853 shares through the Shanghai Stock Exchange trading system, accounting for 0.61% of the company's total share capital of 194,704,350 shares. The highest price of the repurchase transaction was 17.29 yuan/share, the lowest price was 13.79 yuan/share, and the total amount of capital paid was RMB 18,719,512.99 (excluding transaction fees such as stamp duty and transaction fees).
Zhijiang Biotech (688317.SH) reported first-quarter results, net profit of 26.90.69 million yuan, an increase of 346.47% over the previous year
According to Zhitong Finance App News, Zhijiang Biotech (688317.SH) released its report for the first quarter of 2024, achieving revenue of 52.273 million yuan, a year-on-year decrease of 39.27%. Achieved net profit attributable to shareholders of listed companies of 26.90.69 million yuan, an increase of 346.47% over the previous year. Achieved net profit of 258.17,300 yuan after deducting non-recurring profit and loss attributable to shareholders of listed companies, an increase of 267.98% over the previous year.
Zhijiang Biotech (688317.SH) reported 2023 annual results, with a net loss of 137 million yuan, changing from profit to loss over the previous year
Zhijiang Biotech (688317.SH) released its 2023 annual report. The company achieved operating income of 2 during the reporting period...
Zhijiang Biotech (688317.SH): A total of 762,400 shares have been repurchased as of March 31
Gelonghui, April 2, 丨 Zhijiang Biotech (688317.SH) announced that as of March 31, 2024, the company had repurchased 762,357 shares of the company's shares through centralized bidding transactions, accounting for 0.39% of the company's total share capital of 194,704,350 shares. The highest price of the repurchase transaction was 17.29 yuan/share, the lowest price was 15.47 yuan/share, and the total amount of capital paid was RMB 12,370,042.82 (excluding transaction fees such as stamp duty and transaction fees).
No Data